RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerN/A

Registered title, quoted from ClinicalTrials.gov

Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05140746, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed gastric adenocarcinoma through gastroscopy.

    Inclusion criterion 2

  3. ECOG performance status 0-1.

    Inclusion criterion 4

  4. White blood count >4x109/L, Absolute neutrophil count (ANC) >2x109/L, Hemoglobin (Hb)>90g/L, Platelets >100x109/L.

    Inclusion criterion 5

    Serum bilirubin <1.5x ULN; ALT and AST <1.5x ULN.

    Inclusion criterion 7

    Serum creatinine ≤1.5x ULN, or GFR> 60ml/min.

    Inclusion criterion 8

  5. Pregnancy or possibly pregnant woman, breastfeeding woman.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05140746, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion criteria

  • Age between 18-75 years.
  • Histologically confirmed gastric adenocarcinoma through gastroscopy.
  • Resectable gastric cancer.
  • ECOG performance status 0-1.
  • White blood count >4x109/L, Absolute neutrophil count (ANC) >2x109/L, Hemoglobin (Hb)>90g/L, Platelets >100x109/L.
  • Ejection Fraction>50%.
  • Serum bilirubin <1.5x ULN; ALT and AST <1.5x ULN.
  • Serum creatinine ≤1.5x ULN, or GFR> 60ml/min.
  • Agreement to participate in this study with informed consent form.
  • Willingness and ability to comply with the protocol for the duration of the study.
  • No children bearing petential in the next six months before enrollment.

Exclusion criteria

  • With second primary malignant diseases in past five years, exceptions include basal cell and squamous cell carcinoma of the skin that have been cured.
  • Known hypersensitivity reaction to chemotherapy drugs or with contraindications.
  • With severe disease or other unsuitable conditions determined by investigators. Inadequate organ function.
  • With uncontrollable diabetic or fasting blood glucose level ≥11 mmol/L on the test-day.
  • With severe mental symptoms, unconscious or unable to complete the examination.
  • Pregnancy or possibly pregnant woman, breastfeeding woman.
  • Lack of compliance.

Quoted from ClinicalTrials.gov, NCT05140746, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05140746, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05140746